At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)
In Brief
A Phase 2 clinical trial evaluating Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. and Vehicle + Heparin along with best supportive care for Corona Virus Infection and 4 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS).
Study Details
Timeline
Interventions
UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.
Best supportive care treatment per the treating hospital protocol.